ArticleBMC psychiatry2025
CD4 + T lymphocyte and cytokine profiles in depressive disorders.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Comprehensive Analysis of Inflammation Regulatory Biomarkers among three Neuropsychiatric Disorders using Transcriptomic Approach.Neuroinformatics · 2026Article
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundImmune system dysfunction has been associated with depressive disorders; however, the specific alterations in CD4 + T lymphocytes and cytokines among individuals with varying severities of depression remain unclear. This study aimed to investigate the immunological changes in patients with mild, moderate, and severe depression, to identify potential biomarkers for clinical diagnosis and disease severity assessment, and to uncover the immunological mechanisms involved in depression.
methodsTwenty-eight mild depression patients, thirty-one moderate depression patients, twenty-two severe depression patients and eighty-three healthy subjects were included in the mild, moderate, severe and control group. The relative proportions and absolute quantities of Th1, Th2, Th17 and Treg cells in peripheral blood were determined by flow cytometry. In addition, the levels of cytokines in serum were detected by cytometric bead array (CBA), including IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ and TNF-α.
resultsThe levels of Th1%, Th17, Th1/Th2, and Th17/Treg ratios were significantly higher in the mild depression group compared to the control group (p < 0.05), with a concurrent decrease in Treg% (p < 0.05). In the moderate depression group, elevated levels of Th1%, Th17%, Th1, Th17, Th1/Th2, and Th17/Treg were observed (p < 0.05), alongside reduced Treg% and Treg counts (p < 0.05). The severe depression group exhibited further increases in Th1%, Th17%, Th1, Th17, Th1/Th2, and Th17/Treg (p < 0.05). IL-4 levels progressively decreased, while IL-6 levels increased across the mild, moderate, and severe depression groups (p < 0.05). A negative correlation was found between depression severity and IL-4 (r = -0.544, p < 0.001), and a positive correlation with IL-6 (r = 0.553, p < 0.001). IL-4 and IL-6 were identified as independent factors influencing depression severity (p < 0.01).
conclusionsThe study's findings suggest that abnormalities in CD4 + T lymphocytes and cytokines are characteristic of depression across its severity spectrum, with an increase in Th1 and Th17 cells and a decrease in Treg cells. IL-4 and IL-6 may serve as indicators of depression severity and are significant biomarkers for assessing disease progression. These insights enhance our understanding of the immunological basis of depression and provide novel strategies for its management and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.